- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01124747
A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug
May 2, 2014 updated by: Astellas Pharma Inc
An Open-Label Study to Evaluate the Disposition of 14C-Labeled ASP1585 in Healthy Male Volunteers
The objective of this study is to assess the systemic disposition of ASP1585 after oral administration of 14C-labeled drug in healthy male subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subjects will receive study drug for 18 days with a radioactive dose of study drug given on Day 15.
Blood, urine and feces will be collected to confirm recovery of radioactivity.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Body Mass Index (BMI) between 18 and 32 kg/m2, inclusive and minimum body weight 45 kg
- Agrees to sexual abstinence or to use a highly effective form of birth control which includes a barrier method throughout the study
- In good health
Exclusion Criteria:
- History of any clinically significant disease
- History of bowel obstruction, swallowing disorders, gastrointestinal disorders, gastrointestinal surgery, actively bleeding hemorrhoids, or gastric/duodenal ulcers
- Irregular bowel habits (<1 bowel movement per day)
- Clinically significant illness within 30 days
- Received any drug or medicine (prescription or over-the-counter), including topical medications, complementary and alternative medicines and vitamin and mineral supplements within 14 days prior to the first dose of study drug
- Received any investigational medication during the last 30 days or 5 half-lives, whichever is longer, prior to screening
- Consumes >10 units of alcohol per week or history of alcoholism or drug/chemical abuse within past 2 years
- Smokes cigarettes or other nicotine-containing products
- Anticipates an inability to abstain from alcohol use for 48 hours prior to first dose of study drug or from grapefruit, Seville oranges, star fruit or products containing these items from 72 hours prior to first dose of study drug until end of study
- Positive drug or alcohol screen at Screening or Day -1
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or gamma-glutamyl transferase (GGT) value of >2x upper limit of normal at Screening or Day -1
- Known positive for human immunodeficiency virus (HIV), Hepatitis A, Hepatitis B or Hepatitis C
- Unwilling or unable to swallow large numbers of capsules
- Significant blood loss, donated one unit of blood or more, or received a transfusion of any blood or blood product within 60 days or donated plasma within 7 days prior to Day -1
- Known cumulative radiation exposure >5 rems for the whole body, active blood forming organs, ocular lens, and gonads, and >15 rems for other organs
- Has had nuclear medicine procedures, computed tomography scans, or significant x-rays (other than dental) within the past 12 months, has received radiolabeled material within the last 6 months, or has had significant occupational radiation exposure
- Has participated in a radiolabled study within the last 6 months or participated in more than one radiolabeled study within the last 12 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ASP1585 and 14C-Labeled ASP1585
|
Oral
Oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Excretion of radioactivity in urine
Time Frame: Day 15 and up to Day 24
|
Day 15 and up to Day 24
|
Excretion of radioactivity in feces
Time Frame: Day 15 and up to Day 24
|
Day 15 and up to Day 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Radioactivity assessment through analysis of blood samples
Time Frame: Day 15 and up to Day 24
|
Day 15 and up to Day 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Actual)
May 1, 2010
Study Completion (Actual)
May 1, 2010
Study Registration Dates
First Submitted
May 14, 2010
First Submitted That Met QC Criteria
May 14, 2010
First Posted (Estimate)
May 17, 2010
Study Record Updates
Last Update Posted (Estimate)
May 5, 2014
Last Update Submitted That Met QC Criteria
May 2, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 1585-CL-0011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on ASP1585
-
Astellas Pharma IncCompletedRenal Insufficiency | Chronic Kidney Disease | Hyperphosphatemia | Renal DialysisJapan
-
Astellas Pharma IncCompletedA Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal DialysisRenal Insufficiency | Chronic Kidney Disease | Renal DialysisJapan
-
Astellas Pharma IncCompletedHealthy | Urine Phosphorus ExcretionJapan
-
Astellas Pharma IncCompleted
-
Astellas Pharma IncCompletedChronic Kidney DiseaseJapan
-
Astellas Pharma IncCompletedChronic Kidney Disease Patients on Hemodialysis With HyperphosphatemiaJapan
-
Astellas Pharma IncCompletedRenal Insufficiency | Chronic Kidney Disease | HyperphosphatemiaJapan
-
Astellas Pharma IncCompletedA Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisRenal Insufficiency | Chronic Kidney Disease | HyperphosphatemiaJapan
-
Astellas Pharma IncCompletedChronic Renal Failure Patients With Hyperphosphataemia Receiving HemodialysisJapan
-
Astellas Pharma IncCompletedA Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on HemodialysisChronic Kidney Disease | HyperphosphatemiaJapan